Organovo Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Organovo HoldingsDer Gewinn des Unternehmens wird voraussichtlich um 1.6% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 18.1% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 14.2% pro Jahr wachsen.

Wichtige Informationen

-4.3%

Wachstumsrate der Gewinne

23.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.6%
Wachstumsrate der Einnahmen	52.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Feb 10

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Aug 24

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

May 10

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

Jan 04

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

May 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ONVO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2026	0	-15	N/A	N/A	1
3/31/2025	0	-15	N/A	N/A	1
6/30/2024	0	-14	-12	-12	N/A
3/31/2024	0	-15	-15	-15	N/A
12/31/2023	0	-19	-17	-17	N/A
9/30/2023	0	-19	-16	-16	N/A
6/30/2023	0	-18	-16	-15	N/A
3/31/2023	0	-17	-13	-12	N/A
12/31/2022	2	-12	-10	-9	N/A
9/30/2022	2	-12	-10	-10	N/A
6/30/2022	2	-12	-10	-9	N/A
3/31/2022	2	-11	-9	-8	N/A
12/31/2021	N/A	-12	-9	-9	N/A
9/30/2021	N/A	-11	-8	-7	N/A
6/30/2021	N/A	-17	-13	-12	N/A
3/31/2021	N/A	-17	-14	-13	N/A
12/31/2020	N/A	-17	-15	-14	N/A
9/30/2020	0	-18	-14	-14	N/A
6/30/2020	2	-15	-12	-12	N/A
3/31/2020	2	-19	-15	-15	N/A
12/31/2019	3	-23	-17	-17	N/A
9/30/2019	3	-26	-20	-20	N/A
6/30/2019	3	-26	-19	-19	N/A
3/31/2019	3	-27	-20	-20	N/A
12/31/2018	4	-27	-21	-21	N/A
9/30/2018	4	-28	-24	-23	N/A
6/30/2018	4	-32	-25	-25	N/A
3/31/2018	5	-35	N/A	-29	N/A
12/31/2017	4	-38	N/A	-30	N/A
9/30/2017	4	-40	N/A	-31	N/A
6/30/2017	4	-40	N/A	-31	N/A
3/31/2017	4	-38	N/A	-29	N/A
12/31/2016	4	-36	N/A	-29	N/A
9/30/2016	3	-37	N/A	-29	N/A
6/30/2016	2	-39	N/A	-32	N/A
3/31/2016	1	-39	N/A	-29	N/A
12/31/2015	1	-38	N/A	-27	N/A
9/30/2015	1	-35	N/A	-25	N/A
6/30/2015	1	-32	N/A	-23	N/A
3/31/2015	1	-30	N/A	-20	N/A
12/31/2014	0	-29	N/A	-19	N/A
9/30/2014	0	-27	N/A	-19	N/A
6/30/2014	0	-29	N/A	-16	N/A
3/31/2014	0	-26	N/A	-16	N/A
12/31/2013	0	-35	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ONVO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ONVO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ONVO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ONVODie Einnahmen des Unternehmens (18.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ONVODie Einnahmen des Unternehmens (38.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ONVO in 3 Jahren voraussichtlich hoch sein wird

Organovo Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 25%, EPS upgraded

Recent updates

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Organovo Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

New minor risk - Share price stability

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

BICO Reaches Beneficial and Sustainable Solution with Organovo

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Organovo Holdings, Inc. Guides on Patent Portfolio and Successful IPR Defense of Two Patents

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

Organovo Holdings, Inc. Enter into Two Lease Agreements Between Company and San Diego Inspire 1, LLC

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Growth Index

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken